Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine plus cefpodoxime for bacterial upper respiratory tract infections in adults
2007-000260-24Phase 3Terminated
- Sponsor
- Zambon
- Start
- Jul 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bacterial Upper Respiratory Infection, rhinosinusitis, tonsillopharyngitis and 1 more comparing n-acetylcysteine + cefpodoxime proxetil with placebo + cefpodoxime proxetil (2 arms). Primary endpoint: Primary clinical response at day 3 to 4. Started Jul 2007; status: terminated.
02
Drugs
acetylcysteinecefpodoxime
03
Conditions
Bacterial Upper Respiratory Infectionrhinosinusitistonsillopharyngitisotitis media
Beyond the preview
Go deeper on 2007-000260-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000260-24.